Ultragenyx Pharmaceutical (RARE) Accumulated Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Accumulated Expenses data on file, last reported at $194.0 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 12.13% year-over-year to $194.0 million in Q1 2026; TTM through Mar 2026 was $194.0 million, a 12.13% increase from a year earlier, with the FY2025 full-year figure at $89.0 million, down 63.07% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $194.0 million, up from $89.0 million in the prior quarter.
• Over the last five years, Accumulated Expenses for RARE reached as high as $241.0 million in Q4 2024 and fell as low as $47.9 million in Q2 2022.
• Historically, Accumulated Expenses has averaged $129.8 million across 5 years, with a median of $126.4 million in 2022.
• Across the five-year window, Accumulated Expenses jumped 167.28% in 2024 and slumped 63.07% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $78.9 million in 2022, then jumped by 148.91% to $196.5 million in 2023, then advanced by 22.66% to $241.0 million in 2024, then slumped by 63.07% to $89.0 million in 2025, then soared by 117.98% to $194.0 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $194.0 million in Q1 2026, $89.0 million in Q4 2025, and $220.5 million in Q3 2025.